A Phase I Study of Hypofractionated Stereotactic Radiosurgery with Bevacizumab to Treat Recurrent Malignant Glioma

Full Title
A Phase I Dose Escalation Study of Hypofractionated Stereotactic Radiotherapy with Bevacizumab in the Treatment of Recurrent Malignant Glioma

Radiation therapy and bevacizumab are both treatments for malignant gliomas. However, giving radiation therapy after an initial course of treatment has been completed can cause scar tissue and neurologic symptoms. Preliminary evidence indicates that giving radiation with bevacizumab may be more effective than giving either treatment alone.

In this study, researchers want to find the highest dose of radiation therapy that can be given with bevacizumab in patients with glioma that has stopped responding to prior radiation therapy and/or chemotherapy. The radiation will be delivered through a targeted approach called stereotactic radiosurgery.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a confirmed diagnosis of glioma that has stopped responding to prior radiation therapy and/or chemotherapy.
  • At least 3 months must have passed since prior radiation therapy and 4 weeks since any prior chemotherapy and entry into the study.
  • Patients may not have received prior radiosurgery or bevacizumab.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact the Brain Tumor Hotline at 212-639-6767.

Brain Tumors, Primary
Pediatric Brain Tumors: Brain Cancer

Cancer Clinical Trials: Personalizing for Each Patient

Join our experts for a discussion of clinical trials on November 18. Clinical trials can give patients access to new drugs and other treatments before they are widely available, but how do you know if a trial is right for you?

Learn more »